The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

GIST: Imatinib Resistance and Avapritinib for Selected Mutations

Targeted therapy beyond imatinib in PDGFRA D842V and KIT mutant gastrointestinal stromal tumors

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is GIST: Imatinib Resistance and Avapritinib for Selected Mutations?

GIST originate from interstitial cells of Cajal with most cases driven by activating KIT (75-80%) or PDGFRA mutations (5-10%).

PDGFRA D842V mutation accounts for most PDGFRA-mutant GIST and confers complete primary resistance to imatinib.

Imatinib remains first-line therapy for KIT-mutant metastatic GIST with high response rates and prolonged disease control.

Acquired resistance develops in most metastatic cases through secondary KIT mutations affecting drug binding.

Avapritinib provides selective PDGFRA/KIT inhibition with activity in PDGFRA D842V and certain resistant mutations.

Symptoms

GIST typically presents with abdominal pain, mass, gastrointestinal bleeding or incidental imaging finding.
Imaging characteristics include hypervascular submucosal mass with potential central necrosis or cavitation.
Endoscopic biopsy or surgical resection establishes diagnosis with characteristic CD117/DOG1 immunohistochemistry.
Risk stratification considers tumor size, mitotic count and anatomic location for recurrence assessment.
Metastatic disease most commonly involves liver and peritoneum with distinct imaging characteristics.

Risk Factors

Sporadic GIST with somatic KIT or PDGFRA mutations represents most cases.
Hereditary syndromes including familial GIST, Carney triad and Carney-Stratakis syndrome cause subset of cases.
PDGFRA D842V mutations confer primary imatinib resistance requiring upfront alternative therapy selection.
Wild-type GIST without KIT/PDGFRA mutations demonstrates limited imatinib response with alternative driver pathways.
Mutational status evolution during therapy creates need for serial molecular profiling guiding sequential treatment.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • All metastatic GIST require comprehensive molecular testing including mutational analysis guiding therapy selection.
  • Imatinib failure or resistance progression warrants prompt evaluation for sequential targeted therapy options.
  • PDGFRA D842V mutation identification triggers avapritinib consideration as primary or early therapy.
  • Treatment-related toxicities including QTc prolongation, periorbital edema and intracranial hemorrhage with avapritinib require monitoring.
  • Multidisciplinary management with surgical oncology, medical oncology and pathology optimizes complex case management.

Treatment Methods

01
Imatinib 400 mg daily as first-line for KIT-mutant metastatic GIST with dose escalation to 800 mg for exon 9 mutations.
02
Avapritinib 300 mg daily for PDGFRA D842V-mutant GIST with substantial response rates and durable disease control.
03
Sequential KIT-targeted therapy with sunitinib, regorafenib and ripretinib for imatinib-resistant disease progression.
04
Surgical metastasectomy for limited progression on targeted therapy in carefully selected patients.
05
Comprehensive supportive care including monitoring for cognitive effects with avapritinib, surveillance for cardiovascular toxicity, management of treatment-related adverse events and ongoing molecular profiling at progression to guide subsequent therapy lines optimizes outcomes in this molecularly heterogeneous disease.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.